Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial - Henderson, EJ; Lord, SR; Brodie, MA (Lancet Neurol, 2016)
et al.